View Older Stories View More Recent Stories

Jun 24, 2022 08:00AM New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer
Jun 23, 2022 03:43PM AbbVie Declares Quarterly Dividend
Jun 21, 2022 08:01AM AbbVie (ABBV) Submits Supplemental NDA to U.S. FDA for Atogepant to Support Label Expansion for the Preventive Treatment of Migraine
Jun 21, 2022 08:00AM AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
Jun 17, 2022 08:03AM AbbVie (ABBV) Announces SKYRIZI Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Jun 17, 2022 08:00AM SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Jun 11, 2022 08:45AM AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematolo
Jun 10, 2022 05:40AM AbbVie (ABBV) Reports Five-Year Follow Up VENCLYXTO/VENCLEXTA Data Demonstrating 60% of Patients Show Longer PFS
Jun 10, 2022 05:31AM AbbVie (ABBV) Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
Jun 10, 2022 03:15AM AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
Jun 10, 2022 01:05AM New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment
Jun 7, 2022 08:00AM AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting
Jun 1, 2022 10:38AM AbbVie (ABBV) Presents Positive Phase 3 SELECT-AXIS 2 Trials of Upadacitinib Results at EULAR 2022
Jun 1, 2022 10:35AM AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
May 29, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AbbVie, Playstudios, IBM, and Twitter and Encourages Investors to Contact the Firm
May 27, 2022 05:49AM AbbVie (ABBV) Announces Publication from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib
May 27, 2022 03:15AM The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
May 27, 2022 03:00AM The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
May 26, 2022 05:00PM Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 05:00PM Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2022 08:00AM AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference
May 24, 2022 08:00AM AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
May 23, 2022 08:01AM AbbVie (ABBV) Reports Positive Data from Phase 3 Study of Cariprazine
May 23, 2022 08:00AM AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
May 23, 2022 05:27AM AbbVie (ABBV) Announces CHMP Recommendation for EU Approval of Upadacitinib for Treatment of Adults with Moderate to Severe Ulcerative Colitis
May 23, 2022 02:00AM CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis
May 20, 2022 08:15AM AbbVie (ABBV) Submits NDA to U.S. FDA for Investigational ABBV-951 for the Treatment of Advanced Parkinson's Disease
May 20, 2022 08:15AM AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease
May 16, 2022 08:00AM AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®
May 16, 2022 07:32AM AbbVie (ABBV) and Cugene Enter Collaboration in Autoimmune Diseases
May 16, 2022 07:30AM AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
May 13, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and Twitter and Encourages Investors to Contact the Firm
May 13, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and Twitter and Encourages Investors to Contact the Firm
May 12, 2022 11:39AM AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
May 12, 2022 10:00AM Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress
May 12, 2022 10:00AM Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
May 12, 2022 08:30AM AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education
May 11, 2022 08:46AM AbbVie (ABBV) Reports Positive Upadacitinib Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
May 11, 2022 08:45AM Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
May 10, 2022 11:00AM ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
Apr 29, 2022 02:45PM AbbVie (ABBV) Announces RINVOQ Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
Apr 29, 2022 02:44PM RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
Apr 29, 2022 07:43AM AbbVie Reports First-Quarter 2022 Financial Results
Apr 28, 2022 08:30AM Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 28, 2022 08:02AM AbbVie (ABBV) and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
Apr 28, 2022 08:00AM Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
Apr 27, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and Twitter and Encourages Investors to Contact the Firm
Apr 22, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stronghold, AbbVie, Twitter, and Li-Cycle and Encourages Investors to Contact the Firm
Apr 20, 2022 08:01AM AbbVie (ABBV) and Dragonfly Expand Research Collaboration to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
Apr 20, 2022 08:00AM Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
View More Recent Stories View Older Stories